Remove BioTech Remove Medical Billing Remove Meeting Remove Survey
article thumbnail

In U.S. Health Care, It’s Still the Prices, Stupid – But Transparency and Consumer Behavior Aren’t Working As Planned

Health Populi

First, a Wall Street Journal profile of Bluebird Bio , a biotech firm that plans to sell gene-replacement therapy extending annual payments to patients based on whether the drug is effective. As the Harvard Chan-POLITICO study points out, prescription drug costs are top-of-mind for health consumers in America. and 300,000 people worldwide.

BioTech 160
article thumbnail

The Hospital CFO in the Anxiety Economy – My Talk at Cerner’s Now/Next Conference

Health Populi

As patients have taken on more financial responsibility for first-dollar costs in high-deductible health plans and medical bills, hospitals and health care providers face growing fiscal pressures for late payments and bad debt. Over one-half of people told APA that medical bills and the cost of medications were sources of stress.